Key facts
- Daraxonrasib, a new targeted therapy, has nearly doubled survival time for advanced pancreatic cancer patients in a Phase 3 trial.
- The drug's performance is considered a significant breakthrough in pancreatic cancer treatment.
- The drug is administered as a once-daily pill.
Pancreatic cancer has a notoriously low survival rate, making any advancement in treatment a significant development. This new drug's performance in trials offers a potential breakthrough for patients facing a grim prognosis.